You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 140 No. 10, October 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (5)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Radiation Therapy
 •Surgical Oncology
 •Women's Health
 •Women's Health, Other
 •Breast Cancer
 •Alert me on articles by topic

Full-Dose Intraoperative Radiotherapy With Electrons in Breast Surgery

Broadening the Indications

Mattia Intra, MD; Cristina Leonardi, MD; Alberto Luini, MD; Paolo Veronesi, MD; Roberto Gennari, MD; Giovanna Gatti, MD; Mario Ciocca, MD; Javier Soteldo, MD; Fabio Bassi, MD; Marco Venturino, MD; Roberto Orecchia, MD; Umberto Veronesi, MD

Arch Surg. 2005;140:936-939.

Hypothesis  Although postoperative fractionated radiotherapy (PFR) remains the standard method for conservative treatment of breast carcinomas, widespread experience in the use of full-dose intraoperative radiotherapy with electrons (ELIOT) merits its application in novel clinical situations, although long-term results of ongoing clinical trials have not been fully reported.

Design  Retrospective case series.

Setting  Division of breast surgery in a comprehensive cancer center.

Patients  From June 1999 to September 2003 ELIOT was used as the sole radiotherapy in 355 patients with unifocal invasive carcinoma who were candidates for breast-conserving surgery and most of whom were participating in an ongoing institutional trial. In a group of patients in whom PFR was not considered safe or feasible (because of previous mantle field irradiation for Hodgkin disease, cosmetic breast augmentation, severe cardiopathy, large hypertrophic scarring from skin burns, vitiligo, and geographic or social obstacles), ELIOT was performed outside of the ongoing trial.

Results  No particular adverse effects, unusual acute reactions, late sequelae, and local or systemic events were noted in these patients after a mean follow-up of 27.3 months.

Conclusions  In appropriated selected patients, when it is critical to perform PFR after breast-conserving therapy, a single dose of ELIOT may be considered to avoid mastectomy, reduce potential treatment toxicity, improve quality of life, and resolve logistic problems. The long-term results of ongoing clinical trials will further delineate patients in whom ELIOT may replace PFR.


Author Affiliations: Divisions of Breast Surgery (Drs Intra, Luini, P. Veronesi, Gennari, Gatti, Soteldo, Bassi, and U. Veronesi), Radiotherapy (Drs Leonardi and Orecchia), Medical Physics (Dr Ciocca), and Anesthesiology and Intensive Care (Dr Venturino), European Institute of Oncology; and Division of Radiotherapy, University of Milan School of Medicine (Dr Orecchia); Milan, Italy.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intraoperative Radiation Therapy
Willett et al.
JCO 2007;25:971-977.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.